Medical Science Liaison – Neurodegeneration (United States)

Prilenia Therapeutics, a clinical-stage biotechnology company focused on the urgent mission of developing novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, is looking for a Medical Science Liaison (MSL) in the United States, to support programs in both Huntington’s Disease and ALS.

We are a flexible, fast-moving team that is quickly advancing a potential therapy poised to have major impact on the lives of patients and their families. Our lead product candidate, pridopidine, holds Orphan Drug Designation in both Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS) in the U.S. and EU, as well as Fast Track designation from the FDA for the treatment of HD. Prilenia is conducting global Phase 3 clinical trials in both HD and ALS.

​

Pridopidine has the potential to be a pivotal treatment to address HD and ALS disease progression. Prilenia believes pridopidine’s novel mechanism of action as a Sigma-1 receptor agonist also gives it potential in numerous other neurodegenerative and neurodevelopmental conditions.

To learn more about our story and company culture, visit us at https://Prilenia.com 

We are seeking a highly motivated and experienced Medical Science Liaison (MSL) to join our dynamic Medical Affairs team in the United States. This is a field‑based role supporting the U.S. and Canada, and reporting to the Executive Medical Director. The MSL will serve as a scientific expert in HD and ALS while building collaborative partnerships with neurologists, thought leaders and multidisciplinary care teams to support Prilenia’s clinical trials and programs.

Prilenia has offices in the U.S., Israel and The Netherlands. Prilenia is a highly virtual and flexible organization and encourages team members to work in the ways that make them most effective, with a focus on our common goals and drive to move things forward.